Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.
Journal: Leukemia & lymphoma
Published: October 31, 2025
Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic Malignancies.
Journal: Blood
Published: June 04, 2025
Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
Journal: International journal of hematology
Published: January 30, 2024
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
Journal: Science advances
Published: November 29, 2023
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Journal: The Lancet. Haematology
Published: September 19, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Journal: Blood cancer journal
Published: March 30, 2023
Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia.
Journal: Cells
Published: March 11, 2023
Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
Journal: Leukemia
Published: March 05, 2023
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Journal: Cancer discovery
Published: May 23, 2022
Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment.
Journal: Gut
Published: November 15, 2021
Last Updated: 09/26/2026